VBCG
MRTX

Valley Brook Capital Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Valley Brook Capital Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$34K – 457
2021
Q1 		$34K Hold
200
– – 0.03% 261
2020
Q4 		$43K Buy
+200
New +$43.2K 0.04% 210

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Valley Brook Capital Group's MRTX Position: Q2 2021 in Review

Valley Brook Capital Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 200 shares — an estimated $34K sold.

Valley Brook Capital Group first reported a position in MRTX in Q4 2020 and held it in 2 quarters. The position peaked at $43K in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Valley Brook Capital Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Valley Brook Capital Group sold 200 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $34K.
  • Valley Brook Capital Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Valley Brook Capital Group's Mirati Therapeutics, Inc. Common Stock position peaked at $43K in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Valley Brook Capital Group's 13F filing for Q2 2021, filed 22 Jul 2021.